For example, in a patient with Huntington's disease (HD), there is no meaningful way to combine performance on a cognitive test such as the cognitive score of the Unified Huntington's Disease Rating Scale (UHDRS) with dopamine D2 receptor density in the striatum, as determined by PET imaging using 11C raclopride [7-9]. This evidence concerns the gene DRD2 and juvenile Huntington disease.